Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

European shares flat as trade talks, Fed speech spell caution

Published 08/24/2018, 05:36 AM
Updated 08/24/2018, 05:36 AM
© Reuters. FILE PHOTO: Traders work at their desks in front of the German share price index, DAX board, at the stock exchange in Frankfurt

By Julien Ponthus and Helen Reid

LONDON (Reuters) - European shares were little changed on Friday morning as investor digested the latest round of U.S.-China trade talks, which ended without a breakthrough but left open the hope of eventual progress.

Analysts said investors were also likely to exercise caution ahead of a speech later on Friday by Jerome Powell, in which the Federal Reserve chairman is expected to give fresh clues on the outlook for U.S. monetary policy.

"Markets are not very directional today," wrote ActivTrades analyst Pierre Veyret, noting that "the U.S. and China have disappointed investors ...so traders are now patiently waiting for Jerome Powell".

At 0848 GMT, the pan-European STOXX 600 (STOXX) was up 0.1 percent, in a thinner than usual market with trading at 12.7 percent of average daily volumes over the last 90 days.

Miners, banks and cars led gainers.

Autos (SXAP) rose 0.3 percent, after being among the worst-performing sectors earlier in the week since a surprise profit warning from tire maker Continental, which added to ongoing tariff concerns.

Basic materials (SXPP) rose 0.6 percent as London copper prices rose. Antofagasta (L:ANTO) was a top gainer, rising 2.2 percent.

Irish construction company Kingspan (I:KSP) was the top performers, with its shares up 7.7 percent and on track for their best day in over a year after first half results.

Shares in Danish medical equipment maker (CO:AMBUb) recovered from a 12 percent fall on Thursday following a disappointing trading update and were up 7 percent.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Britain's Shire (L:SHP) added 2.3 percent and was the top UK performer after the U.S. Food and Drug Administration approved a drug to treat patients suffering from hereditary angioedema, a hereditary disease that causes swelling in different parts of the body.

Among smaller companies, Swiss semiconductor maker U-Blox sank 15 percent after it cut its guidance for the year, with traders flagging its China business as particularly disappointing.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.